The estimated Net Worth of Katherine J Klein is at least 5.06 百万$ dollars as of 8 March 2024. Katherine Klein owns over 9,791 units of United Therapeutics Corp stock worth over 4,649,678$ and over the last 10 years he sold UTHR stock worth over 0$. In addition, he makes 411,945$ as Independent Director at United Therapeutics Corp.
Sign up
Katherine Klein UTHR stock SEC Form 4 insiders trading
Katherine has made over 4 trades of the United Therapeutics Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 9,791 units of UTHR stock worth 1,211,636$ on 8 March 2024.
The largest trade he's ever made was exercising 9,791 units of United Therapeutics Corp stock on 8 March 2024 worth over 1,211,636$. On average, Katherine trades about 1,033 units every 76 days since 2014. As of 8 March 2024 he still owns at least 13,431 units of United Therapeutics Corp stock.
You can see the complete history of Katherine Klein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Katherine Klein biography
Prof. Katherine J. Klein Ph.D. serves as Independent Director of the Company. Professor Klein has served as the Vice-Dean of the Wharton Social Impact Initiative since July 2012, and as The Wharton School's Edward H. Bowman Professor of Management since 2005. She also served as Professor of Management of The Wharton School from 2004 to 2005. Prior to joining Wharton, Professor Klein was on the faculty of the University of Maryland and a visiting professor at the Stanford Graduate School of Business. She received her B.A. from Yale University, and her Ph.D. in Community Psychology from the University of Texas at Austin. An award-winning organizational psychologist, Professor Klein has conducted extensive field research regarding a range of topics including team leadership, climate, conflict, social networks and effectiveness; organizational change and technology implementation; employee diversity; and employee responses to stock ownership. She has taught executive education and consulted with and studied a variety of for-profit and non-profit organizations including Charles Schwab, Rohm and Haas, North American Scientific, Medtronic, The Baltimore Shock Trauma Center, Penn Vet, the U.S. Census Bureau, and the Korean Management Association. Her research has been published in numerous top journals including Administrative Science Quarterly, Journal of Applied Psychology, the Academy of Management Journal, and the Academy of Management Review. She is also a former associate editor of the Journal of Applied Psychology and Administrative Science Quarterly. Professor Klein is a Fellow of the Academy of Management, the Society for Industrial and Organizational Psychology, the American Psychological Association, and the Association for Psychological Science. She has served as a United Therapeutics director since 2014.
What is the salary of Katherine Klein?
As the Independent Director of United Therapeutics Corp, the total compensation of Katherine Klein at United Therapeutics Corp is 411,945$. There are 17 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of 15,627,500$.
How old is Katherine Klein?
Katherine Klein is 63, he's been the Independent Director of United Therapeutics Corp since 2014. There are 8 older and 12 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.
What's Katherine Klein's mailing address?
Katherine's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.
Insiders trading at United Therapeutics Corp
Over the last 20 years, insiders at United Therapeutics Corp have traded over 68,910,395$ worth of United Therapeutics Corp stock and bought 229,703 units worth 13,655,671$ . The most active insiders traders include Martine A Rothblatt、David Zaccardelli、Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of 2,310,818$. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth 991,341$.
What does United Therapeutics Corp do?
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
What does United Therapeutics Corp's logo look like?
Complete history of Katherine Klein stock trades at United Therapeutics Corp
United Therapeutics Corp executives and stock owners
United Therapeutics Corp executives and other stock owners filed with the SEC include:
-
Martine Rothblatt,
Chairman of the Board, Chief Executive Officer -
Michael Benkowitz,
President, Chief Operating Officer -
Paul Mahon,
Executive Vice President, General Counsel, Corporate Secretary -
James Edgemond,
Chief Financial Officer, Treasurer -
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.,
Founder, Chairman & CEO -
Dr. Martine A. Rothblatt,
Founder, Chairman & CEO -
Michael I. Benkowitz,
Pres & COO -
Paul A. Mahon,
Exec. VP, Gen. Counsel & Corp. Sec. -
Paul A. Mahon J.D.,
Exec. VP, Gen. Counsel & Corp. Sec. -
James C. Edgemond,
CFO & Treasurer -
Christopher Patusky,
Lead Independent Vice Chairman of the Board -
Christopher Causey,
Independent Director -
Richard Giltner,
Independent Director -
Louis Sullivan,
Independent Director -
Tommy Thompson,
Independent Director -
Nilda Mesa,
Independent Director -
Judy Olian,
Independent Director -
Katherine Klein,
Independent Director -
Raymond Kurzweil,
Independent Director -
Raymond Dwek,
Independent Director -
Linda Maxwell,
Director -
Dewey Steadman C.F.A.,
Head of Investor Relations -
Leigh Peterson,
VP of Product Devel. -
Gil Golden,
Sr. VP & Chief Medical Officer -
Patrick Poisson,
Exec. VP of Technical Operations -
Kevin T. Gray,
Sr. VP of Strategic Operations & Logistics -
Holly Hobson,
Associate VP of HR -
Dewey Steadman C.F.A., CFA,
Head of Investor Relations -
Jan Malcolm,
-
Ray Kurzweil,
-
Roger Jeffs,
President & COO -
Fred T Hadeed,
EVP & CFO -
David Zaccardelli,
EVP & Chief Operating Officer -
John Maxim Ferrari,
CFO & Treasurer -
R Paul Gray,
Director -
Lilly & Co Eli,
Director, Chairman and CEO